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Evaluation and biotinlyation of scuPA constructs
The purity of the proteins was analyzed using SDS-PAGE and Western blotting. Anti-6x His-tag ® antibody horseradish peroxidase was used to detect the purified scuPA constructs. The addition of the LPETG motif allowed addition of a GGG-biotin peptide onto the scuPA construct using recombinantly produced Staphylococcus aureus sortase A enzyme. The reaction was performed as previously described 2,3 , using a 1:3:3 molar ratio of scuPA:GGG-biotin:sortase A enzyme. The reaction was performed in sortase reaction buffer (0.5mM calcium chloride, 50mM Tris, 150mM sodium chloride, pH8) for 5 hours at 37°C, shaking at 750rpm. The sortase transpeptidase reaction cleaved off the His-tag motif, which was situated behind the LPETG motif. Therefore, the biotinlyated scuPA constructs did not contain a His-tag. The non-biotinylated scuPA and recombinant sortase A, which were also tagged with a His-tag, were removed using TALON ® metal affinity resin (Clontech, USA) columns, and the excess GGG-biotin was removed via dialysis using a 10 K MWCO membrane (Thermo Fisher Scientific, USA).
Flow cytometry
Platelet-rich plasma (PRP) was obtained by centrifugation of blood which was collected from healthy volunteers. Diluted PRP was either non-activated or activated with 20μM adenosine diphosphate (ADP) before incubation with the purified scFv anti-LIBS constructs, followed by an AlexaFluor 488-coupled labeled anti-His-tag antibody for detection. The activation status of platelets was determined either by a FITC-labeled monoclonal PAC1 antibody (BD Bioscience, USA) or by a PE-labeled monoclonal antibody directed against CD62P (BD Bioscience, USA). Samples were fixed with 1x
CellFix (BD Bioscience, USA) and analyzed by FACS Calibur (BD Bioscience, USA).
The platelet population was distinguished using the forward and sideward light scatter profile.
A gate was set around the platelets and 10,000 cells were analyzed. For single staining, AlexaFluor 488-coupled fluorescence was used to quantify the amount of platelet-bound scFvs. The scFv binding was expressed as mean fluorescence intensity.
Urokinase activity assay
Urokinase activity was determined with a chromogenic substrate assay. Comparison between clinically used uPA (Medac GmbH, Germany) and scuPA was made on the basis of equal urokinase activity. 100nmol/L of scuPA was monitored against commercial uPA standards (0-2000U/mL) used as positive controls. 0.1U/L plasmin was added to activate the scuPA. 0.5mmol/L of S2444 (Chromogenix, Italy) was added and samples were measured on a Victor3V Multi-label counter (PerkinElmer, USA) at a wavelength of 405nm every 5 min over a period of 60 min. Reactions were performed using 100µl total volume.
Plasmin activity assay
The conversion of plasminogen to plasmin using commercial uPA or scuPA was determined in microtiter plates using a chromogenic substrate. 10nmol/L of scuPA was monitored against commercial uPA (0-15U/ml) of and were incubated with 400nmol/L of human glu-plasminogen (Sigma-Aldrich, Germany) and 1mmol/L of S2251 (Chromogenix, Italy). Samples were measured using the Bio-Rad Benchmark Plus (Bio-Rad, USA) at a wavelength of 405nm every 30 sec over a period of 60 min. Reactions were performed using 100µl total volume.
96-well plate fibrinolysis assay
Fibrinolysis activity was determined in microtiter plates. PRP was mixed with 8 mM calcium chloride, 1:50 thromboplastin (Siemens, USA), and 20µM thrombin receptor activator peptide (Sigma-Aldrich, Germany), leading to platelet activation and clotting. The mixture was then incubated with either commercial uPA or biotinylated scuPA. Samples were measured using the Bio-Rad
Benchmark Plus at a wavelength of 405nm every minute over a period of 60 min.
Flow-chamber adhesion assay
Flow-chamber in vitro adhesion assays were performed with glass capillaries (Vitrotubes, USA), which were coated overnight with 100µg/ml collagen (Takeda, Austria). Whole blood was collected Page | 4 from healthy volunteers and was perfused through the capillaries to form microthrombi. 20µg of scFv anti-LIBS and 20µg of scuPA were added to target-ready microbubbles (VisualSonics Inc., Canada), according to the manufacturer's instructions, in order to form targeted theranostic microbubbles (TTMBs). 1x10 6 microbubbles/ml were prefused through the capillaries for 5 minutes. Microthrombi and the binding of microbubbles were visualized with bright field microscopy using the IX81 Olympus microscope (Olympus, USA) and Cell^P 1692 software.
In vivo mouse experiments
Male C57BL/6 mice, 6 to 7 weeks of age (20 to 25g), were used and maintained at the Alfred Medical
Research and Education Precinct Animal Services, and assigned randomly to the different groups. The 
Femoral vein catheterization and ferric chloride injury model for in vivo ultrasound molecular imaging
A catheter was placed into the femoral vein to facilitate injection. Ultrasound of animals was performed with a Vevo2100 high-resolution imaging system (VisualSonics Inc., Canada) using the 40MHz MS550D transducer. Animals were placed on the imaging station after ferric-chlorideinduced injury was performed to induce a thrombus. A small filter paper (2mm x 1mm) saturated with 6% ferric chloride was placed under the left carotid artery of the animal for 3 min. Animals were injected with either LIBS-MBs with commercial uPA, TT-MBs, or LIBS-MBs with saline as the vehicle control.
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Videos and images were acquired before, during, and at several time points after injecting 1.5x10 7 microbubbles in a total volume of 100μl. We have recently established this ultrasound imaging methodology for the detection of thrombi and the monitoring of thrombolysis 1,4 . We injected a high dose of 500U/g of commercial uPA (Medac, Germany), a low dose of 75U/g of commercial uPA, or saline as the vehicle control. Repetitive ultrasound imaging sequences were performed every 5 min for 45 min after thrombolysis. Analysis was performed using VisualSonics imaging software (VisualSonics Inc., Canada). The microbubbles used in this study could also be visualized on an ultrasound scanner that is used on patients (iE33 with L15-7io transducer, Philips).
Histology with hematoxylin and eosin staining
The carotid arteries of mice were embedded in optimal cutting temperature (OCT) compound (Sakura Finetechnical), frozen in liquid nitrogen, and stored at -20°C until sectioning. 6µm thick crosssections of cryosection were prepared using a cryostat (Leica, CM1950) and stained with hematoxylin and eosin.
Assessment of tail bleeding time
An incision to reveal the left jugular vein was made in order to insert a catheter to facilitate injections.
1 min after injecting TT-MBs, LIBS-MBs with commercial uPA, or saline as the vehicle control, the tail was transected 5mm from the tip and immediately submersed in saline at 37°C. The bleeding time was monitored and recorded as the time needed for the cessation of a visible blood flow for 1 min.
Statistical analysis
Unless otherwise specified, data is expressed as mean ± standard error of the mean (SEM). Flow cytometry and data for thrombolysis were analyzed with two-way ANOVA repeated measures analysis using Bonferroni's multiple-comparison post-test. All analyses containing more than two groups were corrected by post hoc analysis and the corrected p-values are given. Statistical analyses were performed using Graphpad Prism 6.0. Ultrasound images were acquired as described in video 1. Reduction in thrombus size and contrast intensity can be seen during the 45 min of ultrasound monitoring. Ultrasound images were acquired as described in video 1. Reduction in thrombus size and contrast intensity can be seen during the 45 min of ultrasound monitoring, demonstrating the imaging/monitoring potential with the concurrent effective thrombolysis at systemic concentrations that do not cause bleeding time prolongation.
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